Background: Calcium-based and non-calcium-based phosphate binders have similar efficacy in the treatment of hyperphosphatemia; however, calcium-based binders may be associated with hypercalcemia, vascular calcification, and adynamic bone disease.
Introduction
Hyperphosphatemia (serum phosphate >5.5 mg/dL) is a highly prevalent condition of end-stage renal disease (ESRD) [1, 2] . Observational studies have established that hyperphosphatemia is associated with adverse clinical outcomes, including all-cause and cardiovascular mortality, in patients with ESRD [3] [4] [5] [6] [7] [8] [9] . The management of hyperphosphatemia in patients with ESRD is challenging and typically requires a combination of dialysis, dietary phosphorus restriction, and oral phosphate binder therapy [10, 11] . The phosphate binders currently used in clinical practice can be broadly classified into calcium-based (calcium acetate/calcium carbonate) and non-calcium-based (sevelamer hydrochloride/ sevelamer carbonate, lanthanum carbonate and iron-based) binders [12] . The binder types have similar efficacy in reducing serum phosphate levels [13] ; however, calcium-based binders have been associated with hypercalcemia, vascular calcification, and adynamic bone disease (low bone turnover) [13] [14] [15] [16] . The impact of calcium-based binders compared with non-calciumbased ones on mortality was evaluated by Jamal et al. [17] in an updated meta-analysis of 11 randomized controlled trials. Patients assigned to non-calcium-based binders were shown to have a 22% reduction in all-cause mortality compared with ISSN: 1740-4398 ORIGINAL RESEARCH -Elemental calcium intake associated with calcium-based phosphate binders drugsincontext.com those assigned to calcium-based binders (risk ratio, 0.78; 95% confidence interval [CI] : 0.61, 0.98).
To address the potential adverse effects of excess calcium load associated with calcium-based binders, the Kidney Disease Outcomes Quality Initiative (KDOQI, 2003) has made a number of guideline recommendations [10] . These include proposals that the maximum daily intake of elemental calcium from calcium-based phosphate binders should be 1.5 g, and that the total daily intake of calcium from both binders and dietary sources should not exceed 2.0 g. In addition, a maximum dialysate calcium concentration of 1.25 mmol/L is recommended to prevent intradialytic calcium loading. It is further suggested that calcium-based phosphate binders should be avoided in patients undergoing dialysis who also have vascular calcification, hypercalcemia, or plasma parathyroid hormone (PTH) levels lower than 150 pg/mL. Thus, the KDOQI guidelines emphasize the importance of minimizing calcium exposure while normalizing serum phosphate levels in patients with ESRD.
There is a need for data to understand the effects of calcium loading associated with calcium-based phosphate binders in patients with ESRD. Here, we describe a post hoc analysis of data from a clinical study of US patients with ESRD [18] . The primary objective was to evaluate elemental calcium intake in patients with ESRD receiving calcium acetate/calcium carbonate monotherapy. The secondary objectives were to evaluate changes in serum phosphate levels, serum calcium levels, and serum PTH levels in patients who switched from calcium acetate/calcium carbonate to lanthanum carbonate monotherapy.
Methods

Primary study design
The study design was described in detail in Vemuri et al. [18] In brief, this was a 16-week, open-label, Phase IV, multicenter study of adult US patients with ESRD and hyperphosphatemia who switched to lanthanum carbonate monotherapy from other phosphate binder regimens, including calcium-based binders, sevelamer hydrochloride, and combination therapies (ClinicalTrials.gov: NCT00160121). The analysis in this article did not involve any new studies of human or animal subjects. There was an initial screening visit and a 1-week observation period during which patients remained on their previous phosphate binder therapy with no dose modifications permitted ( Figure 1 ). After the observation period, patients began a 12-week lanthanum carbonate titration period (starting dose, 1500 mg/day; target maximum dose, 3750 mg/day) without washout to achieve serum phosphate levels within the KDOQI target range of 3.5-5.5 mg/dL [10] . Patients then continued lanthanum carbonate treatment for an additional 4-week maintenance period. Serum phosphate concentration was measured at four time points: screening, baseline (end of the 1-week observation period on previous phosphate binder therapy [week 0]), end of the lanthanum carbonate titration (week 12), and maintenance (week 16). The intent-to-treat (ITT) population (N=2520) included all patients who received at least one dose of lanthanum carbonate and were assessed for at least one efficacy evaluation. Safety assessments for the overall population are described in the primary study [18] ; 
Results
Post hoc analysis population Table 2 ). The most commonly reported reason for study discontinuation was adverse events (n=252 [14.3%] ). Baseline demographic and clinical characteristics were similar in the post hoc analysis population and in the excluded patients (Table 3) . these data were not summarized for the set analyzed in this post hoc analysis.
The study protocol was approved by an Institutional Review Board, and written, informed consent was obtained from all patients before study participation.
Post hoc analysis
Analysis population
The post hoc analysis population comprised patients in the ITT population who had received previous calcium acetate/calcium carbonate monotherapy, and had recorded dose data for calcium acetate/calcium carbonate at baseline and lanthanum carbonate at week 16.
Phosphate binder dose formulations
Calcium acetate was taken in just one formulation (PhosLo * ), comprising 667 mg tablets/capsules (elemental calcium, 169 mg), whereas calcium carbonate was taken in a variety of formulations, including generic calcium carbonate, Tums † , and Os-Cal ‡ ( The results of the current analysis raise important questions regarding the impact on calcium balance (net intake minus net excretion) of oral calcium from calcium-based phosphate binders. Several studies have investigated calcium balance in patients with ESRD. Hill et al. demonstrated in a study of eight patients with chronic kidney disease that intake of calcium carbonate was associated with a positive calcium balance compared with patients receiving placebo [22] . Sigrist and McIntyre [21] reported that all of their study patients taking calcium-based binders (n=26) had a positive calcium balance. Here, it should be noted that serum calcium is not a good ISSN: 1740-4398 ORIGINAL RESEARCH -Elemental calcium intake associated with calcium-based phosphate binders drugsincontext.com proxy for calcium balance because more than 99% of total body calcium is stored dynamically in bone; less than 1% exists in the extracellular space. Thus, excess calcium intake does not manifest as hypercalcemia in healthy individuals [23] or in patients with ESRD [21, 24] . This is supported by research from Byrne et al., who reported that an excessive calcium intake may coexist with a normal serum calcium level in patients undergoing hemodialysis [25] . Our results are consistent with Baseline elemental calcium intake stratum (g/day)
KDOQI maximum recommended elemental calcium from phosphate binders=1.5 g/day KDOQI maximum recommended total calcium from binders and dietary sources=2.0 g/day KDOQI maximum recommended elemental calcium from phosphate binders=1.5 g/day KDOQI maximum recommended total calcium from binders and dietary sources=2.0 g/day A, mean corrected serum calcium levels; B, mean PTH levels. Bars show mean (95% CI). Patients were stratified based on their elemental calcium intake from calcium acetate monotherapy. CI, confidence interval; KDOQI, Kidney Disease Outcomes Quality Initiative; PTH, parathyroid hormone.
A large number of studies have reported that calcium-based binder use is associated with vascular calcification [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . Furthermore, significantly higher all-cause mortality has been reported in patients receiving calcium-based versus noncalcium-based phosphate binders [17] . This is of particular interest, considering that calcium-based binders are more commonly prescribed than non-calcium-based binders [37] . However, not all studies have found an association between calcium-based binders and vascular calcification [38, 39] . In one study, in which the majority of participants were prescribed ISSN: 1740-4398 ORIGINAL RESEARCH -Elemental calcium intake associated with calcium-based phosphate binders drugsincontext.com calcium-based binders, KDOQI targets for serum calcium levels were achieved by 57.8% of patients [37] . Nevertheless, cardiovascular events were reported in 76.0% of patients, and calcification was reported in 41.8%, 34.1% of which was caused by vascular calcification [37] . Furthermore, vascular calcification typically occurs in ~70% of patients with stage 3-4 chronic kidney disease [40] , for whom calcium-based binders or calcium supplements are rarely prescribed, arguing against [23] . Interestingly, in the subset of patients who received the highest doses of calcium acetate (≥2.5 g/day elemental calcium), mean PTH levels were higher than 500 pg/mL at both baseline and week 16. These high PTH levels are probably related to the high phosphate levels in these patients [41] ; mean phosphate levels were 6.7 mg/dL at baseline and 7.1 mg/dL at week 16.
There is an association between serum phosphate levels above the KDOQI-recommended range and poor outcomes, including mortality and cardiovascular complications, in patients with ESRD [10] . One study demonstrated that phosphate levels over 6.2 mg/dL were associated with cardiovascular complications ISSN: 1740-4398 ORIGINAL RESEARCH -Elemental calcium intake associated with calcium-based phosphate binders drugsincontext.com lanthanum carbonate, in line with the primary study design, cannot be ruled out.
Additional information on dialysis adequacy, dietary phosphorus intake, urinary phosphorus excretion, and residual renal function would be useful for further interpretation of the results; however, these data were not collected in the original study. Furthermore, in some respects, patients served as their own controls because the same patients were studied before and after switching treatment. As such, it is less likely that dialysis adequacy, dietary phosphorus intake, residual renal function, and urinary phosphorus excretion changed before and after switching.
Conclusions
This post hoc analysis of real-world clinical data shows that a large proportion of patients with ESRD taking calcium acetate/ calcium carbonate monotherapy to treat hyperphosphatemia ingest elemental calcium at levels above the KDOQIrecommended daily limits. These patients may be at risk of developing vascular calcification and adynamic bone disease.
It is important to consider these findings when decisions are made regarding the comparative utility of calcium-based phosphate binders over non-calcium-based phosphate binders in patients with ESRD. [42] ; two further studies demonstrated that the relative risk of mortality increased with serum phosphate levels over 6.5 mg/dL [43] and 7.0 mg/dL [44] . Overall, mean serum phosphate levels tended to remain stable after switching from calcium carbonate or calcium acetate to lanthanum carbonate. Nevertheless, levels were elevated (>5.5 mg/dL) at baseline and after switching, particularly in those with a baseline elemental calcium intake of 2.0 g/day to <2.5 g/day and ≥2.5 g/day. This suggests that very high doses of calcium-based binders were being used in an unsuccessful attempt to control serum phosphate levels. Thus, despite the use of calcium-based binders in doses that frequently exceed the recommended amount of elemental calcium, achieving phosphorus control remains challenging in real-world practice. This is supported by an observational study of 8265 patients in Japan, Europe, and the United States receiving hemodialysis, which demonstrated that 52% had serum phosphate concentrations above the upper target of 5.5 mg/dL, despite the fact that 81% of all patients were taking phosphate binders (of those, ~80% were taking calcium-based binders) [9] .
Limitations of the current analysis include those inherent to post hoc analyses [45] . The lack of dietary calcium data meant that the total calcium exposure could not be calculated. 
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